EGFR and non-small cell lung carcinoma: suggest that the conjoint utilization of gefitinib and betulinol can transcend the resistance observed in EGFR wild-type/kras-mutated NSCLC cells to gefitinib, heralding a new pathway for the treatment of such lung cancer manifestations (65).